×
ZIVO Bioscience Price/Book Ratio 2016-2024 | ZIVO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
ZIVO Bioscience price/book ratio from 2016 to 2024. Price/book ratio can be defined as
View More
ZIVO Bioscience Price/Book Ratio 2016-2024 | ZIVO
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
ZIVO Bioscience price/book ratio from 2016 to 2024. Price/book ratio can be defined as
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$168.1B
Vertex Pharmaceuticals (VRTX)
$119.2B
Regeneron Pharmaceuticals (REGN)
$113.7B
Gilead Sciences (GILD)
$102.4B
Bristol Myers Squibb (BMY)
$101.3B
CSL (CSLLY)
$95.4B
GSK (GSK)
$84.1B
Alnylam Pharmaceuticals (ALNY)
$35B
Argenex SE (ARGX)
$32.8B
Biogen (BIIB)
$27.5B
BioNTech SE (BNTX)
$27.5B
Moderna (MRNA)
$24.5B
BeiGene (BGNE)
$20.1B
Illumina (ILMN)
$20.1B
Genmab (GMAB)
$15.8B
BioMarin Pharmaceutical (BMRN)
$13.1B
Vaxcyte (PCVX)
$12.7B
Exact Sciences (EXAS)
$12.5B
Insmed (INSM)
$12.5B
Incyte (INCY)
$12.2B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.9B
QIAGEN (QGEN)
$10.1B
Bio-Rad Laboratories (BIO.B)
$9.1B
Roivant Sciences (ROIV)
$8.7B
Ascendis Pharma (ASND)
$8.5B
Legend Biotech (LEGN)
$7.9B
Intra-Cellular Therapies (ITCI)
$7.9B
Repligen (RGEN)
$7.8B
Exelixis (EXEL)
$7.4B